Research
Hormonal
MBS leads to marked improvements in sexual function for both men and women, including increased libido, erectile function, and hormonal normalization, typically within the first 12 months.
Expect significant improvements in sexual function and hormonal health within the first year after surgery. These changes are driven by weight loss and hormonal recalibration. Address any performance anxiety through counseling to maximize benefits.
ModerateSupportsMEDIUM confidence
Growing evidence indicates that MBS confer marked sexual-health benefits to men as well as women... average + 8-point gain in the total International Index of Erectile Function (IIEF)... total testosterone typically rises by 5–8 nmol L⁻1, SHGB nearly doubles... obesity-related hypogonadism resolves in up to 60% of men.
Why this rating
Based on meta-analyses and prospective studies, but heterogeneity exists.
Source
The Implications of Metabolic and Bariatric Surgery on Psychosocial and Relational Health: A Narrative Review
Tommaso Dionisi et al. · Obesity Surgery · 2025
DOI 10.1007/s11695-025-08193-w
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Metabolic and bariatric surgery (MBS) significantly improves self-esteem, body image, and health-related quality of life, with the greatest gains occurring within the first 12 months post-surgery.Moderate
- MBS is associated with a higher risk of divorce or separation compared to the general population, particularly within the first five years post-surgery.Moderate
- Family involvement and structured family therapy significantly enhance postoperative weight loss, adherence, and psychosocial outcomes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →